Published in J Pathol on June 01, 2001
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med (2010) 3.43
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol (2012) 1.09
Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep (2012) 1.08
Preinvasive breast cancer. Annu Rev Pathol (2010) 1.08
Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer (2004) 1.00
[Prognostic factors in ductal carcinoma in situ]. Pathologe (2006) 1.00
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res (2003) 0.99
Measures of benefit for breast screening from the pathology database for Scotland, 1991-2001. J Clin Pathol (2003) 0.98
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Protein biomarkers for the early detection of breast cancer. Int J Proteomics (2011) 0.98
Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res (2012) 0.94
Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer (2004) 0.93
Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer (2010) 0.91
ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas. J Cancer (2012) 0.86
Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study. Virchows Arch (2012) 0.85
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
8p deletion is strongly linked to poor prognosis in breast cancer. Cancer Biol Ther (2015) 0.77
Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. PLoS One (2013) 0.77
Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development. Oncotarget (2015) 0.77
Histopathologic indicators of breast cancer biology: insights from population mammographic screening. Br J Cancer (2005) 0.77
Cytogenetic differences in breast cancer samples between German and Japanese patients. J Clin Pathol (2005) 0.76
Genomic heterogeneity of breast tumor pathogenesis. Clin Med Oncol (2009) 0.76
Molecular Classification of Lobular Carcinoma of the Breast. Sci Rep (2017) 0.75
Aberrantly expressed mRNAs and long non-coding RNAs in patients with invasive ductal breast carcinoma: a pilot study. Mol Med Rep (2014) 0.75
The diagnostic challenge of low-grade ductal carcinoma in situ. Eur J Cancer (2017) 0.75
Genome evolution in ductal carcinoma in situ: invasion of the clones. J Pathol (2016) 0.75
[Genome-wide expression profiling as a clinical tool: are we there yet?]. Pathologe (2009) 0.75
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Flexible regression models with cubic splines. Stat Med (1989) 14.45
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Signaling of cell fate decisions by CLAVATA3 in Arabidopsis shoot meristems. Science (1999) 8.61
Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60
The CONSTANS gene of Arabidopsis promotes flowering and encodes a protein showing similarities to zinc finger transcription factors. Cell (1995) 7.76
Dependence of stem cell fate in Arabidopsis on a feedback loop regulated by CLV3 activity. Science (2000) 6.05
Plasmid vectors for the genetic analysis and manipulation of rhizobia and other gram-negative bacteria. Methods Enzymol (1986) 5.58
High frequency mobilization of gram-negative bacterial replicons by the in vitro constructed Tn5-Mob transposon. Mol Gen Genet (1984) 5.35
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68
The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium. Ann Emerg Med (1999) 4.59
Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst (1998) 4.32
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Statistical aspects of prognostic factor studies in oncology. Br J Cancer (1994) 4.22
Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer Res Treat (2012) 3.99
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Bayesian variable selection method for censored survival data. Biometrics (1998) 3.84
Testing for qualitative interactions between treatment effects and patient subsets. Biometrics (1985) 3.71
A molecular link between stem cell regulation and floral patterning in Arabidopsis. Cell (2001) 3.55
Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep (1978) 3.38
Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (1986) 3.22
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95
A new family of RSF1010-derived expression and lac-fusion broad-host-range vectors for gram-negative bacteria. Gene (1990) 2.89
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
Demonstration of high-fidelity simulation team training for emergency medicine. Acad Emerg Med (1999) 2.82
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol (2005) 2.70
Extension of the host range of Escherichia coli vectors by incorporation of RSF1010 replication and mobilization functions. J Bacteriol (1985) 2.70
Simulation based teamwork training for emergency department staff: does it improve clinical team performance when added to an existing didactic teamwork curriculum? Qual Saf Health Care (2004) 2.60
Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer (1993) 2.60
Confidence intervals for reporting results of clinical trials. Ann Intern Med (1986) 2.49
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer (2006) 2.45
High-frequency conjugal plasmid transfer from gram-negative Escherichia coli to various gram-positive coryneform bacteria. J Bacteriol (1990) 2.42
Doxorubicin gradients in human breast cancer. Clin Cancer Res (1999) 2.36
The Comprehensive assessment and Referral Evaluation (CARE)--rationale, development and reliability. Int J Aging Hum Dev (1977) 2.35
Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol (2001) 2.33
The development of plasmid-free strains of Agrobacterium tumefaciens by using incompatibility with a Rhizobium meliloti plasmid to eliminate pAtC58. Plasmid (1985) 2.33
A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet (1994) 2.30
Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J (1997) 2.27
Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res (2004) 2.26
Length biased sampling in etiologic studies. Am J Epidemiol (1980) 2.23
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst (1992) 2.16
Efficacy of selected diagnostic tests for sexually transmitted diseases. JAMA (1976) 2.15
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Radioactive seed localization for non-palpable breast cancer. Br J Surg (2013) 2.07
A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med (1984) 2.06
Measures of explained variation for survival data. Stat Med (1990) 2.06
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists. Control Clin Trials (1995) 2.04
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg (1998) 2.02
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
On the efficiency of targeted clinical trials. Stat Med (2005) 1.99
Practical Bayesian guidelines for phase IIB clinical trials. Biometrics (1994) 1.99
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 1.94
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Relationships between vascularization and proliferation in invasive breast cancer. J Pathol (1999) 1.90
Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst (1991) 1.85
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Evidence that childhood acute lymphoblastic leukemia is associated with an infectious agent linked to hygiene conditions. Cancer Causes Control (1998) 1.78
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol (1999) 1.77
Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol (1999) 1.76
Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst (1996) 1.76
[The sentinel node procedure: standard intervention for surgical treatment of breast cancer]. Ned Tijdschr Geneeskd (1998) 1.76
Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest (1995) 1.75
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol (1998) 1.71
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Genetics of xanthan production in Xanthomonas campestris: the xanA and xanB genes are involved in UDP-glucose and GDP-mannose biosynthesis. J Bacteriol (1992) 1.68
Statistical design of reverse dye microarrays. Bioinformatics (2003) 1.68
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst (1993) 1.66
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene (2007) 1.63
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol (1998) 1.62
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Parallels between UNUSUAL FLORAL ORGANS and FIMBRIATA, genes controlling flower development in Arabidopsis and Antirrhinum. Plant Cell (1995) 1.60
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology (2003) 1.59
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol (1996) 1.58
Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol (1998) 1.58
The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene (2007) 1.57